Allergan Aesthetics Expands SKINVIVE by JUVÉDERM to 35 New Markets Globally

What's Happening?

Allergan Aesthetics, a subsidiary of AbbVie, has announced the expansion of its SKINVIVE by JUVÉDERM product into 35 additional markets worldwide, bringing the total to 57 international launches in 2025. SKINVIVE is a hydrating injectable designed to improve facial skin quality, offering long-lasting hydration and smoothness with a single treatment. This expansion is part of Allergan Aesthetics' strategic commitment to enhancing global skin quality, responding to consumer demand for health-focused skincare solutions. The company aims to empower practitioners with innovative injection techniques and treatment approaches, aligning with the growing trend towards natural-looking aesthetic results.

Why It's Important?

The expansion of SKINVIVE by JUVÉDERM underscores the increasing consumer interest in skin health and quality, reflecting a shift in the aesthetics market towards products that offer natural enhancements rather than dramatic changes. This move positions Allergan Aesthetics as a leader in the global skincare industry, potentially increasing its market share and influence. The focus on skin quality aligns with broader trends in health and wellness, appealing to consumers who prioritize vitality and youthfulness. As the global skin quality market is valued at $5.2 billion, Allergan's strategic expansion could significantly impact its revenue and growth prospects.

What's Next?

Allergan Aesthetics plans to showcase its AA Signature approach at the Aesthetic Anti-Aging Medicine World Congress in Dubai, highlighting its commitment to holistic skin quality improvement. The company will continue to advance efforts in skin quality through strategic product launches and partnerships, aiming to meet the evolving needs of aesthetic patients worldwide. Healthcare professionals can expect further innovations in Allergan's injectable portfolio, enhancing treatment outcomes and patient satisfaction. The expansion into new markets will likely drive increased demand for SKINVIVE, prompting Allergan to explore additional opportunities for growth and development in the aesthetics sector.